Human fibroblast interferon in treatment of viral diseases of the skin and mucous membranes.
The therapeutic effect of human fibroblast interferon (HFIF) was studied in 33 patients. Seven had ophthalmic lesions (three due to adenovirus Type 8, four to herpes simplex virus, and one to herpes zoster) and were treated with HFIF. In the four patients with herpes simplex keratitis, HFIF was given in addition to standard therapy or together with other antiviral agents. Ten other patients, 8 with herpes simplex or herpes zoster skin or mucous membrane lesions, were treated with HFIF. HFIF was incorporated into an ointment as well as into a solution for subconjunctival infections. Although the number of cases was small, our results showed that HFIF was effective in shortening the course of the disease.
D000257:Adenoviridae Infections / Q000628:therapy*; D000258:Adenovirus Infections, Human / Q000628:therapy*; D000328:Adult; D000368:Aged; D002648:Child; D002675:Child, Preschool; D005260:Female; D006560:Herpes Labialis / Q000628:therapy; D006561:Herpes Simplex / Q000628:therapy*; D006562:Herpes Zoster / Q000628:therapy*; D006563:Herpes Zoster Ophthalmicus / Q000628:therapy; D006801:Humans; D007370:Interferon Type I / Q000627:therapeutic use*; D007634:Keratitis / Q000628:therapy; D007635:Keratitis, Dendritic / Q000628:therapy*; D008297:Male; D008875:Middle Aged
D007370:Interferon Type I